Objective To evaluate the efficacy of icotinib as first-line therapy in advanced non-small-cell lung cancer( NSCLC) patients with sensitive EGFR mutation. Methods Clinical data of 51 advanced NSCLC patients with sensitive EGFR mutation receiving icotinib treatment were retrospectively reviewed. Patients were treated with icotinib 125 mg,po,tid. until disease progression or unacceptable toxicity. Efficacy and adverse effects were analyzed. Results Among51 patients,exon 19 deletion was detected in 29 cases,ex...